Clearside Biomedical names Carol Hoang as VP medical affairs
Clearside Biomedical (NASDAQ:CLSD) appointed Carol Hoang to the position of VP of medical affairs.
Dr. Hoang, who brings more than 17 years of experience across multiple sectors of the global healthcare industry to Clearside, was most recently VP of medical affairs for DigiSight Technologies, a digital health company developing mobile solutions to enhance vision care for patients and doctors.
She also has served as global executive medical director at Novartis Pharma, leading the global medical strategy in ophthalmology. And before joining Novartis, she held senior marketing and medical affairs positions at Genentech, where she helped launch Lucentis in 2006.
“Carol is a seasoned executive with a strong track record of success managing medical affairs for both large and emerging ophthalmic companies,” Clearside president and CEO, Daniel White, said in a statement.
“Her ability to build advocacy and create compelling scientific communication platforms will be a tremendous asset as we continue to plan for Clearside’s potential transition from a clinical-stage to a commercial-stage company,” he added.